Amber M Gedlinske1, Carrie M Stephan1, Shelley R H Mockler1, Katie M Laubscher1, Karla S Laubenthal1, Cameron D Crockett1, M Bridget Zimmerman1, Katherine D Mathews2. 1. From the Department of Pediatrics (A.M.G., C.M.S., C.D.C., K.D.M.) and Center for Disabilities and Development (S.R.H.M., K.M.L., K.S.L.), University of Iowa Hospitals and Clinics; and Department of Biostatistics (M.B.Z.), University of Iowa College of Public Health, Iowa City. C.D.C. is now affiliated with Washington University, St. Louis, MO. 2. From the Department of Pediatrics (A.M.G., C.M.S., C.D.C., K.D.M.) and Center for Disabilities and Development (S.R.H.M., K.M.L., K.S.L.), University of Iowa Hospitals and Clinics; and Department of Biostatistics (M.B.Z.), University of Iowa College of Public Health, Iowa City. C.D.C. is now affiliated with Washington University, St. Louis, MO. katherine-mathews@uiowa.edu.
Abstract
OBJECTIVE: To test the hypothesis that we will be able to detect change in motor outcome measures over time in a cohort with mutations in FKRP. METHODS: Individuals with documented FKRP mutations were evaluated annually with a battery of established motor outcome measures including limited quantitative myometry and timed function measures. Results were analyzed using random coefficient regression to determine annual change in each measure. Due to the nonlinear progression through the lifespan of the study participants, pediatric (<19 years) and adult (≥19 years) cohorts were analyzed separately. Effect of genotype was evaluated in each cohort. RESULTS: Sixty-nine participants (30 pediatric, 44 adult) with at least 2 evaluations were included. There was a small but statistically significant decline in timed motor function measures in both pediatric and adult cohorts. Genotype significantly affected rate of decline in the pediatric but not the adult cohort. Some pediatric patients who are homozygous for the c.826C>A mutation showed improving motor performance in adolescence. Performance on the 10-meter walk/run was highly correlated with other timed function tests. CONCLUSIONS: There is a slow annual decline in motor function in adults with FKRP mutations that can be detected with standard motor outcome measures, while the results in the pediatric population were more variable and affected by genotype. Overall, these analyses provide a framework for development of future clinical trials. The dystroglycanopathies natural history study (Clinical Trial Readiness for the Dystroglycanopathies) may be found on clinicaltrials.gov (NCT00313677).
OBJECTIVE: To test the hypothesis that we will be able to detect change in motor outcome measures over time in a cohort with mutations in FKRP. METHODS: Individuals with documented FKRP mutations were evaluated annually with a battery of established motor outcome measures including limited quantitative myometry and timed function measures. Results were analyzed using random coefficient regression to determine annual change in each measure. Due to the nonlinear progression through the lifespan of the study participants, pediatric (<19 years) and adult (≥19 years) cohorts were analyzed separately. Effect of genotype was evaluated in each cohort. RESULTS: Sixty-nine participants (30 pediatric, 44 adult) with at least 2 evaluations were included. There was a small but statistically significant decline in timed motor function measures in both pediatric and adult cohorts. Genotype significantly affected rate of decline in the pediatric but not the adult cohort. Some pediatric patients who are homozygous for the c.826C>A mutation showed improving motor performance in adolescence. Performance on the 10-meter walk/run was highly correlated with other timed function tests. CONCLUSIONS: There is a slow annual decline in motor function in adults with FKRP mutations that can be detected with standard motor outcome measures, while the results in the pediatric population were more variable and affected by genotype. Overall, these analyses provide a framework for development of future clinical trials. The dystroglycanopathies natural history study (Clinical Trial Readiness for the Dystroglycanopathies) may be found on clinicaltrials.gov (NCT00313677).
Authors: M Poppe; L Cree; J Bourke; M Eagle; L V B Anderson; D Birchall; M Brockington; M Buddles; M Busby; F Muntoni; A Wills; K Bushby Journal: Neurology Date: 2003-04-22 Impact factor: 9.910
Authors: Anna Mayhew; Elena S Mazzone; Michelle Eagle; Tina Duong; Maria Ash; Valerie Decostre; Marlene Vandenhauwe; Katrijn Klingels; Julaine Florence; Marion Main; Flaviana Bianco; Erik Henrikson; Laurent Servais; Giles Campion; Elizabeth Vroom; Valeria Ricotti; Natalie Goemans; Craig McDonald; Eugenio Mercuri Journal: Dev Med Child Neurol Date: 2013-08-01 Impact factor: 5.449
Authors: Maja Poppe; John Bourke; Michelle Eagle; Patrick Frosk; Klaus Wrogemann; Cheryl Greenberg; Francesco Muntoni; Thomas Voit; Volker Straub; David Hilton-Jones; Cheerag Shirodaria; Kate Bushby Journal: Ann Neurol Date: 2004-11 Impact factor: 10.422
Authors: Eugenio Mercuri; Martin Brockington; Volker Straub; Susana Quijano-Roy; Yeliz Yuva; Ralf Herrmann; Susan C Brown; Silvia Torelli; Victor Dubowitz; Derek J Blake; Norma B Romero; Brigitte Estournet; Caroline A Sewry; Pascale Guicheney; Thomas Voit; Francesco Muntoni Journal: Ann Neurol Date: 2003-04 Impact factor: 10.422
Authors: Craig M McDonald; Erik K Henricson; Jay J Han; R Ted Abresch; Alina Nicorici; Gary L Elfring; Leone Atkinson; Allen Reha; Samit Hirawat; Langdon L Miller Journal: Muscle Nerve Date: 2010-04 Impact factor: 3.217
Authors: Alexander P Murphy; Jasper Morrow; Julia R Dahlqvist; Tanya Stojkovic; Tracey A Willis; Christopher D J Sinclair; Stephen Wastling; Tarek Yousry; Michael S Hanna; Meredith K James; Anna Mayhew; Michelle Eagle; Laurence E Lee; Jean-Yves Hogrel; Pierre G Carlier; John S Thornton; John Vissing; Kieren G Hollingsworth; Volker Straub Journal: Ann Clin Transl Neurol Date: 2019-05-16 Impact factor: 4.511